FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 336:393-398 February 6, 1997 Number 6 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.

Methods In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed.

Results After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned to six months of therapy (20.7 percent) and 3 in the group assigned to continuing therapy (2.6 percent). The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8.0 (95 percent confidence interval, 2.5 to 25.9). There were 13 major hemorrhages, 3 in the six-month group (2.7 percent) and 10 in the indefinite-treatment group (8.6 percent). The relative risk of major hemorrhage in the six-month group, as compared with the indefinite-treatment group, was 0.3 (95 percent confidence interval, 0.1 to 1.1). There was no difference in mortality between the two groups.

Conclusions Prophylactic oral anticoagulation that was continued for an indefinite period after a second episode of venous thromboembolism was associated with a much lower rate of recurrence during four years of follow-up than treatment for six months. However, there was a trend toward a higher risk of major hemorrhage when anticoagulation was continued indefinitely.

Source Information

From the Departments of Internal Medicine at Karolinska Hospital, Stockholm (S.S., P.L.), Huddinge Hospital, Huddinge (M.H.), Danderyd Hospital, Danderyd (A.C.), Köping Hospital, Köping (P.N.), Södertälje Hospital, Södertälje (S.-G.E.), Västerås Central Hospital, Västerås (S.N.), Södersjukhuset, Stockholm (G.L.), St. Göran Hospital, Stockholm (B.L.), Örebro Regional Hospital, Örebro (O.L.), and Nacka Hospital, Stockholm (E.L.); and the Department of Radiology, Ersta Hospital, Stockholm (S.G.) — all in Sweden. Other authors were Hans Walter, M.D., Sabbatsberg Hospital, Stockholm; Stanka Viering, M.D., Norrtälje Hospital, Norrtälje; Martin Hjorth, M.D., Lidköping Hospital, Lidköping; and Jonas Boberg, M.D., Uppsala Academic Hospital, Uppsala.

Address reprint requests to Dr. Schulman at the Department of Internal Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden.

Full Text of this Article

Related Letters:

Venous Thromboembolism
Block J. A., White T. M., Fetrow C.W., Schulman S., The Duration of Anticoagulation Trial Study Group , Diuguid D. L.
Extract | Full Text  
N Engl J Med 1997; 337:51-53, Jul 3, 1997. Correspondence

This article has been cited by other articles:

• Giannakopoulos, B., Krilis, S. A. (2009). How I treat the antiphospholipid syndrome. Blood 114: 2020-2030 [Abstract] [Full Text]  
• Komiyama, T., Coppola, J. M., Larsen, M. J., van Dort, M. E., Ross, B. D., Day, R., Rehemtulla, A., Fuller, R. S. (2009). Inhibition of Furin/Proprotein Convertase-catalyzed Surface and Intracellular Processing by Small Molecules. J. Biol. Chem. 284: 15729-15738 [Abstract] [Full Text]  
• Prandoni, P., Prins, M. H., Lensing, A. W.A., Ghirarduzzi, A., Ageno, W., Imberti, D., Scannapieco, G., Ambrosio, G. B., Pesavento, R., Cuppini, S., Quintavalla, R., Agnelli, G., for the AESOPUS Investigators, (2009). Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis: A Randomized Trial. ANN INTERN MED 150: 577-585 [Abstract] [Full Text]  
• Moores, L. K. (2009). Pulmonary Vascular Diseases. ACCP Pulmonary Med Brd Rev 25: 21-38 [Full Text]  
• Schellong, S. M., Bounameaux, H., Büller, H. R. (2009). CHAPTER 37 Venous Thromboembolism. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Kearon, C., Julian, J. A., Kovacs, M. J., Anderson, D. R., Wells, P., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., Gent, M., Ginsberg, J. S., for the ELATE Investigators, (2008). Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 112: 4432-4436 [Abstract] [Full Text]  
• Authors/Task Force Members, , Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galie, N., Pruszczyk, P., Bengel, F., Brady, A. J.B., Ferreira, D., Janssens, U., Klepetko, W., Mayer, E., Remy-Jardin, M., Bassand, J.-P., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Zamorano, J.-L., Andreotti, F., Ascherman, M., Athanassopoulos, G., De Sutter, J., Fitzmaurice, D., Forster, T., Heras, M., Jondeau, G., Kjeldsen, K., Knuuti, J., Lang, I., Lenzen, M., Lopez-Sendon, J., Nihoyannopoulos, P., Perez Isla, L., Schwehr, U., Torraca, L., Vachiery, J.-L. (2008). Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29: 2276-2315 [Full Text]  
• Legnani, C., Palareti, G., Cosmi, B., Cini, M., Tosetto, A., Tripodi, A., for the PROLONG Investigators (on behalf of FCSA a, (2008). Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. haematol 93: 900-907 [Abstract] [Full Text]  
• Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]  
• Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J. (2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S-545S [Abstract] [Full Text]  
• MADHWAL, S., LINCOFF, A. M., ROLSTON, D. D.K. (2008). Q: Should patients on long-term warfarin take aspirin for heart disease?. Cleveland Clinic Journal of Medicine 75: 206-208 [Full Text]  
• Koscielny, J., Kiesewetter, H., Jorg, I., Harenberg, J. (2007). Ximelagatran for Treatment and Prophylaxis of Recurrent Events in Deep Vein Thrombosis. CLIN APPL THROMB HEMOST 13: 299-307 [Abstract]  
• Snow, V., Qaseem, A., Barry, P., Hornbake, E. R., Rodnick, J. E., Tobolic, T., Ireland, B., Segal, J., Bass, E., Weiss, K. B., Green, L., Owens, D. K., The Joint American College Of Physicians/american, (2007). Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 5: 74-80 [Abstract] [Full Text]  
• Scarvelis, D., Wells, P. S. (2006). Diagnosis and treatment of deep-vein thrombosis.. CMAJ 175: 1087-1092 [Abstract] [Full Text]  
• Ho, W. K., Hankey, G. J., Quinlan, D. J., Eikelboom, J. W. (2006). Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.. Arch Intern Med 166: 729-736 [Abstract] [Full Text]  
• Aujesky, D., Smith, K. J., Cornuz, J., Roberts, M. S. (2005). Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism. Chest 128: 1601-1610 [Abstract] [Full Text]  
• Ost, D., Tepper, J., Mihara, H., Lander, O., Heinzer, R., Fein, A. (2005). Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis. JAMA 294: 706-715 [Abstract] [Full Text]  
• Gulseth, M. P. (2005). Ximelagatran: An orally active direct thrombin inhibitor. Am J Health Syst Pharm 62: 1451-1467 [Abstract] [Full Text]  
• Hirsh, J., O'Donnell, M., Weitz, J. I. (2005). New anticoagulants. Blood 105: 453-463 [Abstract] [Full Text]  
• Goldhaber, S. Z. (2004). Prevention of Recurrent Idiopathic Venous Thromboembolism. Circulation 110: IV-20-IV-24 [Abstract] [Full Text]  
• Agnelli, G., Becattini, C., Prandoni, P., Nieto, J. A., Monreal, M., the RIETE Investigators, , Kahn, S. R., Boari, B., Salmi, R., Manfredini, R., Morita, H., Nagai, R., Ross, D. J., Kyrle, P. A., Eichinger, S., Weltermann, A. (2004). Recurrent Venous Thromboembolism in Men and Women. NEJM 351: 2015-2018 [Full Text]  
• Dager, W. E, Vondracek, T. G, McIntosh, B. A, Nutescu, E. A (2004). Ximelagatran: An Oral Direct Thrombin Inhibitor. The Annals of Pharmacotherapy 38: 1881-1897 [Abstract] [Full Text]  
• Wittkowsky, A. K. (2004). Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism. Journal of Pharmacy Practice 17: 308-316 [Abstract]  
• Linkins, L.-A., Pasquale, P., Paterson, S., Kearon, C. (2004). Change in Thrombus Length on Venous Ultrasound and Recurrent Deep Vein Thrombosis. Arch Intern Med 164: 1793-1796 [Abstract] [Full Text]  
• Weitz, J. I., Hirsh, J., Samama, M. M. (2004). New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 265S-286S [Abstract] [Full Text]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E. (2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 401S-428S [Abstract] [Full Text]  
• Kearon, C. (2004). Long-Term Management of Patients After Venous Thromboembolism. Circulation 110: I-10-I-18 [Abstract] [Full Text]  
• Kyrle, P. A., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A., Eichinger, S. (2004). The Risk of Recurrent Venous Thromboembolism in Men and Women. NEJM 350: 2558-2563 [Abstract] [Full Text]  
• Elliott, C. G., Rubin, L. J. (2004). Mars or Venus -- Is Sex a Risk Factor for Recurrent Venous Thromboembolism?. NEJM 350: 2614-2616 [Full Text]  
• Goldhaber, S. Z., Nadel, E. S., King, M. E., Sharma, A. (2004). Case 17-2004 - A 42-Year-Old Woman with Cardiac Arrest Several Weeks after an Ankle Fracture. NEJM 350: 2281-2290 [Full Text]  
• Vaknansky, A., Kupfer, Y., Tessler, S., Boger, C., Schroll, S., Holmer, S., Schulman, S., Eriksson, H. (2004). Ximelagatran for Secondary Prevention of Venous Thromboembolism. NEJM 350: 618-619 [Full Text]  
• Goldhaber, S. Z., Elliott, C. G. (2003). Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention. Circulation 108: 2834-2838 [Full Text]  
• Linkins, L.-A., Choi, P. T., Douketis, J. D. (2003). Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis. ANN INTERN MED 139: 893-900 [Abstract] [Full Text]  
• Huisman, M. V., van der Meer, F. J.M., van Rooden, C. J., Malik, V., Kupfer, Y., Tessler, S., Tran, H. A., Brotman, D. J., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., Kearon, C., Julian, J. A., Ginsberg, J. S., Buller, H. R., Prins, M. H. (2003). Low-Intensity versus Conventional-Intensity Warfarin for Prevention of Recurrent Venous Thromboembolism. NEJM 349: 2164-2167 [Full Text]  
• Schulman, S., Wahlander, K., Lundstrom, T., Clason, S. B., Eriksson, H., the THRIVE III Investigators, (2003). Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. NEJM 349: 1713-1721 [Abstract] [Full Text]  
• Frazee, L. A, Chomo, D. L (2003). Duration of Anticoagulant Therapy After Initial Idiopathic Venous Thromboembolism. The Annals of Pharmacotherapy 37: 1489-1496 [Abstract] [Full Text]  
• Heit, J. A. (2003). The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. Chest 124 : 40S-48S [Abstract] [Full Text]  
• Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., Gent, M., the Extended Low-Intensity Anticoagulation for Thr, (2003). Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. NEJM 349: 631-639 [Abstract] [Full Text]  
• Schulman, S. (2003). Care of Patients Receiving Long-Term Anticoagulant Therapy. NEJM 349: 675-683 [Full Text]  
• van Dongen, C. J.J., Prins, M. H., Buller, H. R., Seneviratne, C., Kupfer, Y., Tessler, S., Krishnan, J. A., Streiff, M. B., Cosmi, B., Palareti, G., Aberegg, S. K., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., the PREVENT Investigators, (2003). Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 349: 398-400 [Full Text]  
• Hyers, T. M. (2003). Duration of Anticoagulation in Venous Thromboembolism. Arch Intern Med 163: 1265-1266 [Full Text]  
• van Dongen, C. J. J., Vink, R., Hutten, B. A., Buller, H. R., Prins, M. H. (2003). The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event: A Meta-analysis. Arch Intern Med 163: 1285-1293 [Abstract] [Full Text]  
• (2003). British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58: 470-483 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full Text]  
• Ridker, P. M, Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., Glynn, R. J., the PREVENT Investigators, (2003). Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 348: 1425-1434 [Abstract] [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 107: 1692-1711 [Full Text]  
• Prandoni, P., Lensing, A. W.A., Prins, M. H., Bernardi, E., Marchiori, A., Bagatella, P., Frulla, M., Mosena, L., Tormene, D., Piccioli, A., Simioni, P., Girolami, A. (2002). Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. ANN INTERN MED 137: 955-960 [Abstract] [Full Text]  
• Dalen, J. E. (2002). Pulmonary Embolism: What Have We Learned Since Virchow?: Treatment and Prevention. Chest 122: 1801-1817 [Full Text]  
• Joffe, H. V, Goldhaber, S. Z (2002). Laboratory thrombophilias and venous thromboembolism. Vasc Med 7: 93-102 [Abstract]  
• Simioni, P., Tormene, D., Prandoni, P., Zerbinati, P., Gavasso, S., Cefalo, P., Girolami, A. (2002). Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 99: 1938-1942 [Abstract] [Full Text]  
• Rosendaal, F.R., Helmerhorst, F.M., Vandenbroucke, J.P. (2002). Female Hormones and Thrombosis. Arterioscler. Thromb. Vasc. Bio. 22: 201-210 [Abstract] [Full Text]  
• Kearon, C. (2002). Long term and short term oral anticoagulation treatments were equivalent for venous thromboembolism. Evid. Based Med. 7: 16-16 [Full Text]  
• Kearon, C. (2002). 3 months and 1 year of oral anticoagulant treatment were equivalent for idiopathic proximal deep venous thrombosis. Evid. Based Med. 7: 17-17 [Full Text]  
• Bauer, K. A., Rosendaal, F. R., Heit, J. A. (2002). Hypercoagulability: Too Many Tests, Too Much Conflicting Data. ASH Education Book 2002: 353-368 [Abstract] [Full Text]  
• Reissig, A., Heyne, J.-P., Kroegel, C. (2001). Sonography of Lung and Pleura in Pulmonary Embolism : Sonomorphologic Characterization and Comparison With Spiral CT Scanning. Chest 120: 1977-1983 [Abstract] [Full Text]  
• Bauer, K. A. (2001). The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications. ANN INTERN MED 135: 367-373 [Abstract] [Full Text]  
• Tait, R C (2001). Anticoagulation in patients with thromboembolic disease. Thorax 56: ii30-37 [Full Text]  
• Van Aken, H., Bode, C., Darius, H., Diehm, C., Encke, A., Gulba, D. C., Haas, S., Hacke, W., Puhl, W., Quante, M., Riess, H., Scharf, R., Schellong, S., Schror, K., Schulte, K.-L., Tebbe, U. (2001). State-of-the-Art Review: Anticoagulation: The Present and Future. CLIN APPL THROMB HEMOST 7: 195-204 [Abstract]  
• Marchetti, M., Quaglini, S., Barosi, G. (2001). Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 94: 365-372 [Abstract] [Full Text]  
• Ray, J. G., Mamdani, M., Tsuyuki, R. T., Anderson, D. R., Yeo, E. L., Laupacis, A. (2001). Use of Statins and the Subsequent Development of Deep Vein Thrombosis. Arch Intern Med 161: 1405-1410 [Abstract] [Full Text]  
• Miles, J. S., Miletich, J. P., Goldhaber, S. Z., Hennekens, C. H., Ridker, P. M. (2001). G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37: 215-218 [Abstract] [Full Text]  
• Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., Deykin, D. (2001). Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 119 : 8S-21S [Full Text]  
• Levine, M. N., Raskob, G., Landefeld, S., Kearon, C. (2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest 119 : 108S-121S [Full Text]  
• Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., Weg, J. G. (2001). Antithrombotic Therapy for Venous Thromboembolic Disease. Chest 119 : 176S-193S [Full Text]  
• Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., Ginsberg, J. S. (2000). Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy. Arch Intern Med 160: 3431-3436 [Abstract] [Full Text]  
• Simioni, P., Prandoni, P., Lensing, A. W. A., Manfrin, D., Tormene, D., Gavasso, S., Girolami, B., Sardella, C., Prins, M., Girolami, A. (2000). Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96: 3329-3333 [Abstract] [Full Text]  
• Beyth, R. J (2000). The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high. Evid. Based Med. 5: 188-188 [Full Text]  
• Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., Eichinger, S. (2000). High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. NEJM 343: 457-462 [Abstract] [Full Text]  
• (2000). Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 21: 1301-1336  
• Streiff, M. B. (2000). Vena caval filters: a comprehensive review. Blood 95: 3669-3677 [Abstract] [Full Text]  
• Verstraete, M., Prentice, C. R. M., Samama, M., Verhaeghe, R. (2000). A European View on the North American Fifth Consensus on Antithrombotic Therapy. Chest 117: 1755-1770 [Abstract] [Full Text]  
• Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., Melton III, L. J. (2000). Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Cohort Study. Arch Intern Med 160: 761-768 [Abstract] [Full Text]  
• Hansson, P.-O., Sorbo, J., Eriksson, H. (2000). Recurrent Venous Thromboembolism After Deep Vein Thrombosis: Incidence and Risk Factors. Arch Intern Med 160: 769-774 [Abstract] [Full Text]  
• Horne III, M. K., Chang, R. (1999). Thrombolytic Therapy for Deep Venous Thrombosis?. JAMA 282: 2164-2166 [Abstract] [Full Text]  
• Sanson, B.-J., Simioni, P., Tormene, D., Moia, M., Friederich, P. W., Huisman, M. V., Prandoni, P., Bura, A., Rejto, L., Wells, P., Mannucci, P. M., Girolami, A., Buller, H. R., Prins, M. H. (1999). The Incidence of Venous Thromboembolism in Asymptomatic Carriers of a Deficiency of Antithrombin, Protein C, or Protein S: A Prospective Cohort Study. Blood 94: 3702-3706 [Abstract] [Full Text]  
• Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., MacKinnon, B., Julian, J. A., Johnston, M., Douketis, J., Roberts, R., van Nguyen, P., Kassis, J., Dolan, S., Demers, C., Desjardins, L., Solymoss, S., Trowbridge, A. (1999). A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. NEJM 340: 901-907 [Abstract] [Full Text]  
• Schafer, A. I. (1999). Venous Thrombosis as a Chronic Disease. NEJM 340: 955-956 [Full Text]  
• Borrowman, T., Love, R., Mason, J. W. (1999). Dilated Cardiomyopathy: Problems in Diagnosis and Management. Chest 115: 569-571 [Full Text]  
• Verstraete, M. (1999). Prevention and treatment of venous thromboembolism after major trauma. Trauma 1: 39-51 [Abstract]  
• Ludemann, P., Nabavi, D. G., Junker, R., Wolff, E., Papke, K., Buchner, H., Assmann, G., Ringelstein, E. B. (1998). Factor V Leiden Mutation Is a Risk Factor for Cerebral Venous Thrombosis : A Case-Control Study of 55 Patients. Stroke 29: 2507-2510 [Abstract] [Full Text]  
• Goldhaber, S. Z. (1998). Pulmonary Embolism. NEJM 339: 93-104 [Full Text]  
• Haire, W. D. (1998). Vena Caval Filters for the Prevention of Pulmonary Embolism. NEJM 338: 463-464 [Full Text]  
• Goldhaber, S. Z (1998). Clinical overview of venous thromboembolism. Vasc Med 3: 35-40 [Abstract]  
• Ridker, P. M, PREVENT Investigators, (1998). Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 3: 67-73 [Abstract]  
• Stoschitzky, K., Stark, G., Dacar, D., van der Wouw, P. A., Bax, M. (1997). Massive Pulmonary Embolism. NEJM 337: 1561-1562 [Full Text]  
• Hirsh, J., Kearon, C., Ginsberg, J. (1997). Duration of Anticoagulant Therapy After First Episode of Venous Thrombosis in Patients With Inherited Thrombophilia. Arch Intern Med 157: 2174-2177 [Abstract]  
• Becker, R. C., Ansell, J. (1997). The Need for Long-Term Anticoagulants in Venous Thromboembolism: How Long?. CLIN APPL THROMB HEMOST 3: S8-S15  
• Vassalli, G., Dichek, D. A (1997). Gene therapy for arterial thrombosis. Cardiovasc Res 35: 459-469 [Abstract] [Full Text]  
• Block, J. A., White, T. M., Fetrow, C.W., Schulman, S., The Duration of Anticoagulation Trial Study Group, , Diuguid, D. L. (1997). Venous Thromboembolism. NEJM 337: 51-53 [Full Text]  
• (1997). Duration of Anticoagulation for Recurrent PE or DVT. Journal Watch Cardiology 1997: 7-7 [Full Text]  
• (1997). INDEFINITE ANTICOAGULATION FOR RECURRENT VENOUS THROMBOSIS. JWatch General 1997: 6-6 [Full Text]  
• Diuguid, D. L. (1997). Oral Anticoagulant Therapy for Venous Thromboembolism. NEJM 336: 433-434 [Full Text]